Immunoglobulin G-insulin antibodies and immune region-associated alloantigens in insulin-dependent diabetes mellitus.
The present study was undertaken to determine the importance of immune region-associated alloantigens for susceptibility to insulin-dependent diabetes (IDD), their possible influence on immunoglobulin G-insulin antibody formation, and their clinical significance. Incidence of DRw3 and DRw4 (HLA D-related immune region-associated alloantigens; w, defined by sera dispensed during the Seventh International Histocompatibility Workshop) was found with significantly increased frequency in the IDD patients (n = 50) compared to healthy individuals (n = 107). Subjects positive for DRw3 carry a 4.5-fold increased risk and those positive for DRw4 carry a 2.5-fold increased risk of developing IDD. By analyzing immunoglobulin G-insulin antibody titers in DRw3-positive and DRw3-negative patients (all treated with conventional Lente insulin), a significant tendency for high insulin-binding capacity (IBC) was noted in the latter group, yielding a mean IBC of 2.24 in DRw3-negative and 0.74 in DRw3-positive diabetics (P less than 0.02). A significantly increased insulin dosage was needed for adequate metabolic control in those patients with high IBC (IBC greater than 3.0 U/liter). Patients with high IBC and high insulin requirements were predominantly found to be DRw3 negative. Our data demonstrate that IDD is more closely associated with DRw3 than with all hitherto described HLA A, B, and C locus alloantigens of the major histocompatibility complex. In addition, these immunogenetic factors seem to be of clinical importance by influencing the humoral antiinsulin immune response.
D000293:Adolescent; D000328:Adult; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G; D007328:Insulin / Q000627:therapeutic use; D007330:Insulin Antibodies; D007519:Isoantigens
D007074:Immunoglobulin G; D007328:Insulin; D007330:Insulin Antibodies; D007519:Isoantigens